Windward Bio Raises Funds in Nasdaq IPO, Shares Surge 68%
Clinical-stage biotech Windward Bio debuted on Nasdaq at $17 per share and closed its first trading day at $28.50, a gain of roughly 68%.
Windward Bio, a clinical-stage biotechnology company backed by Qiming Venture Partners, made its public market debut on Nasdaq on November 13, 2026, trading under the ticker symbol WWB after pricing its initial public offering at $17.00 per share.
Shares closed the first trading session at $28.50, representing a gain of approximately 68% over the IPO price — a strong opening performance that signals robust investor appetite for the Shanghai-linked immunology-focused biotech.
Read more W.T.B. Financial Declares $1.85 Quarterly Common Dividend →
The company is described as innovative within the immunology space, though the breadth of its clinical pipeline and the total capital raised in the offering were not disclosed in the initial announcement. Qiming Venture Partners, a prominent venture firm with deep ties to China's life sciences sector, is listed as the primary institutional backer behind the listing.
The debut adds Windward Bio to a growing cohort of Asia-linked biotechnology firms seeking access to U.S. public capital markets via Nasdaq, which remains the preferred exchange for clinical-stage life sciences companies. A strong first-day pop of this magnitude can reflect both underlying investor enthusiasm and the relatively constrained float typical of early-stage biotech IPOs.
Continue reading at All Financial Services & Investing.